schizophrenia

Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study

Authors: Robert Goldman, Antony Loebel, Josephine Cucchiaro, Ling Deng, Robert L Findling

Journal: Journal of Child and Adolescent Psychopharmacology

Year Published: 2017

Objective: To evaluate the efficacy and safety of lurasidone in acutely symptomatic adolescent patients with schizophrenia. Methods: Patients aged 13-17 years were randomly assigned to 6 weeks of double-blind, fixed-dose lurasidone (40 or 80 mg/day) or […]

The Effect of Adjunctive Mangosteen Pericarp on Cognition in People With Schizophrenia: Secondary Analysis of a Randomized Controlled Trial

Authors: Wolfgang Marx, David R Skvarc, Mohammadreza Mohebbi, Adam J Walker, Alcy Meehan, Alyna Turner, Andrea Baker, Seetal Dodd, Sue M Cotton, James Graham Scott, Bianca E Kavanagh, Melanie M Ashton, Ellie Brown, John J McGrath, Michael Berk, Olivia May Dean

Journal: Frontiers in Psychiatry

Year Published: 2021

Background Cognitive impairment is prevalent and often highly burdensome in people with schizophrenia. The aim of this study was to investigate if mangosteen (Garcinia mangostana Linn.) pericarp extract may be an effective intervention to improve cognitive […]

Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D 1 receptor positive allosteric modulator in patients with schizophrenia

Authors: Amit Desai, Lauren Benner, Ruishan Wu, Lev Gertsik, Paul Maruff, Gregory A Light, Tolga Uz, Gerard J Marek, Tong Zhu

Journal: Neuropsychopharmacology

Year Published: 2020

ASP4345, a novel dopamine D1 receptor positive allosteric modulator, is being evaluated for the treatment of cognitive impairment associated with schizophrenia (CIAS). This phase 1 multiple ascending-dose study (NCT02720263) assessed the safety, tolerability, and pharmacodynamics of […]

Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia

Authors: Brian J Miller, Andrei Pikalov, Cynthia O Siu, Michael Tocco, Joyce Tsai, Philip D Harvey, John W Newcomer, Antony Loebel

Journal: Comprehensive Psychiatry

Year Published: 2020

Background: Accumulating evidence has implicated insulin resistance and inflammation in the pathophysiology of cognitive impairments associated with neuropsychiatric disorders. This post-hoc analysis based on a placebo-controlled trial investigated the effect of inflammation (indexed by CRP) and […]

Relation between retinal vascular abnormalities and working memory impairment in patients with schizophrenia and bipolar disorder

Authors: Abhishek Appaji, Bhargavi Nagendra, Dona Maria Chako, Ananth Padmanabha, Arpitha Jacob, Chaitra V Hiremath, Shivarama Varambally, Muralidharan Kesavan, Ganesan Venkatasubramanian, Shyam Vasudeva Rao, Carroll A.B. Webers, Tos T.J.M. Berendschot, Naren P. Rao

Journal: Asian Journal of Psychiatry

Year Published: 2020

Emerging evidence indicates abnormal retinal micro-vasculature in schizophrenia (SCZ) and bipolar disorder (BD) and its relation to cognitive functions. However, the association of these abnormalities with the cognitive deficits in these disorders has not been examined till date.

1 2 3 6

Back to Publications